Omar Duramad

Dr. Duramad has over 15 years of industry experience in Immunology research and early drug development for both small molecule and antibody therapeutics, leading programs from early discovery through to IND Filing. Prior to BryoLogyx, he was the founder & CEO of Abmuno Therapeutics, a company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and infectious diseases. Notably, he led the early development of a checkpoint therapeutic antibody to TIGIT, which was out-licensed to Arcus Biosciences for clinical development. Prior to Abmuno, he held a variety of positions with increasing responsibility at IGM Biosciences, Neothera Biosciences, and REGiMMUNE, leading immunology research & preclinical teams focused on oncology and autoimmune disease indications. As a researcher at Dynavax Technologies, he was part of the Drug Discovery group that identified novel Toll-like Receptor inhibitors for diseases such as lupus, psoriasis, and rheumatoid arthritis. Additionally, Dr. Duramad previously advised multiple clients including Loxo Oncology, Sirenas MD, Holoclara, and REGiMMUNE, each a biopharmaceutical company and iQ Biosciences, an Immunology focused contract research organization, regarding early development programs, therapeutic or technical platform development.

An immunologist by training, Dr. Duramad has received several awards such as the Schissler Foundation Fellowship in Cancer Research, American Legion Auxiliary Fellowship for Outstanding Scholarship, and the Vivian L. Smith Award for Outstanding Immunologist. He has been an invited speaker at prestigious conferences such as Keystone Symposia, American Society of Hematology, and American Transplant Congress. Dr. Duramad obtained his BS in Biochemistry & Cell Biology from University of California, San Diego and PhD in Immunology & Cancer Biology from the University of Texas, MD Anderson Cancer Center in Houston.